BridgeBio have substantially advanced this progress of the novel treatment for cardiac amyloidosis, leveraging the investigational drug. Early patient data suggests potential improvements for patients suffering from this debilitating illness. This effort underscores researchers’ focus to treating critical healthcare requirements in a heart space.